Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment

Mohmood B Aldapt; Nancy Kassem; Randa Al-Okka; Rula Ghasoub; Dina Soliman; Mohammad A Abdulla; Deena Mudawi; Feryal Ibrahim; Mohamed A Yassin

doi:10.23750/abm.v89i3-S.7218

Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment

Authors

Mohmood B Aldapt Resident, Internal Medicine, Hamad Medical Corporation (HMC), Doha, Qatar
Nancy Kassem Clinical Pharmacist, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar
Randa Al-Okka Clinical Pharmacist, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar
Rula Ghasoub Clinical Pharmacist, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar
Dina Soliman Specialist, Hematopathology, Laboratory Medicine, Hamad Medical Corporation (HMC) and National Cancer Institute Cairo University, Cairo, Egypt
Mohammad A Abdulla Clinical Fellow, Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha
Deena Mudawi Clinical Fellow, Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha
Feryal Ibrahim 5 Consultant Hematopathologist Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar
Mohamed A Yassin Consultant, Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar

Keywords:

Thrombocytosis, all-trans retinoic (ATRA) acid, promyelocytic leukaemia

Abstract

We present a rather uncommon side effect observed in a 20-year-old man with acute promyelocytic leukemia during treatment with ATRA. He developed a high platelet counts reaching up to 1655×10⁹/L on day 29 of ATRA treatment, and started to recover spontaneously on day 33 of treatment, without any change in ATRA, or adding any cytoreduction therapy. No complications associated with thrombocytosis were observed. IL-6 seems to play an important role in the pathogenesis of the thrombocytosis induced by ATRA. However, it is unclear what are the precipitating factors for this rare phenomenon and whether it is caused by certain predisposing factors that might be related to patient’s, disease pathogenesis or other unknown factors.

Downloads

Published

03-04-2018

Issue

Vol. 89 No. 3-S (2018): Haematological malignancies in Qatar: from childhood to adulthood

Section

CASE REPORTS

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

How to Cite

Aldapt MB, Kassem N, Al-Okka R, et al. Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment. Acta Biomed. 2018;89(3-S):33-37. doi:10.23750/abm.v89i3-S.7218

Download Citation